Locations:
Search
Mixed results from phase 2 CALLIPER trial of novel dual-action compound
Long-awaited efficacy against disability progression in nonrelapsing SPMS appears to be at hand
MRI classifier identifies a subset of patients with disease marked by cortical atrophy, not demyelination
Findings challenge dogma that microglia are exclusively destructive regardless of location in brain
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
New review distills insights from studies over the past decade
Single-arm, open-label study offers proof of concept for MSC-NTF cells
Panel outlines research priorities around a promising alternative to imaging markers
Three criteria for finding an effective treatment for neurodegeneration
Paves way for phase 3 testing of novel treatment approach
Advertisement
Advertisement